Ranking · Unmet Need
Trial Gap Index
Burden percentile minus active-trial percentile within the same scope. Positive values flag cancers with high mortality burden but comparatively few active trials. A quantitative signal, not an accusation (CLAUDE.md §324). Caveat (Phase 1): trial counts aggregate a cancer and its NCIt descendants only; registrations phrased at a broader level (e.g. "colorectal cancer" for colon and rectal cancer) are attributed to the broader entity, which can overstate the gap of narrower top-level sites.
Computedci-trial-gap-v1unit: percentile pointshigher = worseAll metrics
| Rank | Δ | Cancer | Trial Gap Index (percentile points) | Percentile | Confidence | Sources | Why #n? |
|---|---|---|---|---|---|---|---|
| 1 | = | Malignant Colon Neoplasm | +50 | 100 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606921 |
| 2 | ▲2 | Malignant Bladder Neoplasm | +23.3 | 96.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606922 |
| 3 | = | Cutaneous Melanoma | +20 | 93.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606923 |
| 4 | ▲1 | Malignant Laryngeal Neoplasm | +16.7 | 90 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606925 |
| 4 | ▲2 | Malignant Pancreatic Neoplasm | +16.7 | 90 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606924 |
| 6 | ▲3 | Malignant Vulvar Neoplasm | +10 | 83.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606926 |
| 7 | ▲4 | Malignant Rectal Neoplasm | +6.7 | 80 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606927 |
| 8 | ▲2 | Malignant Kidney Neoplasm | +6.6 | 76.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606928 |
| 9 | ▲3 | Malignant Esophageal Neoplasm | +3.4 | 73.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606929 |
| 10 | ▲4 | Malignant Anal Neoplasm | +3.4 | 70 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606930 |
| 11 | ▲3 | Malignant Salivary Gland Neoplasm | +3.3 | 66.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606931 |
| 12 | ▲2 | Malignant Testicular Neoplasm | +3.3 | 63.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606932 |
| 12 | ▲1 | Malignant Vaginal Neoplasm | +3.3 | 63.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606933 |
| 14 | = | Malignant Mesothelioma | +3.3 | 56.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606934 |
| 15 | ▼1 | Malignant Liver Neoplasm | 0 | 53.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606936 |
| 15 | ▼1 | Malignant Lung Neoplasm | 0 | 53.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606935 |
| 15 | ▼1 | Malignant Prostate Neoplasm | 0 | 53.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606937 |
| 18 | ▲13 | Malignant Thyroid Gland Neoplasm | -3.3 | 43.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606938 |
| 19 | ▲6 | Malignant Hypopharyngeal Neoplasm | -3.3 | 40 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606939 |
| 20 | ▲2 | Malignant Breast Neoplasm | -3.4 | 36.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606940 |
| 20 | ▲4 | Malignant Central Nervous System Neoplasm | -3.4 | 36.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606941 |
| 22 | ▲4 | Malignant Penile Neoplasm | -6.7 | 30 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606942 |
| 23 | ▲3 | Leukemia | -10 | 26.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606943 |
| 23 | ▲5 | Malignant Ovarian Neoplasm | -10 | 26.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606944 |
| 23 | ▲6 | Malignant Uterine Corpus Neoplasm | -10 | 26.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606945 |
| 26 | ▲5 | Non-Hodgkin Lymphoma | -16.6 | 16.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606946 |
| 27 | ▲6 | Malignant Gastric Neoplasm | -16.7 | 13.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606947 |
| 28 | ▲6 | Malignant Cervical Neoplasm | -20 | 10 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606949 |
| 28 | ▲2 | Multiple Myeloma | -20 | 10 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606948 |
| 30 | ▲5 | Hodgkin Lymphoma | -20 | 3.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606950 |
| 31 | ▲5 | Malignant Nasopharyngeal Neoplasm | -30 | 0 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606951 |
Data updated 16 hours agoSource updated unknown31 eligible entities · inputs hash 14c2f4c76893f07853ff87fb